- Home
- PROK vs TSI Comparison
PROK vs TSI Comparison
Compare PROK & TSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- TSI
- Stock Information
- Founded
- PROK 2015
- TSI 1987
- Country
- PROK United States
- TSI United States
- Employees
- PROK N/A
- TSI N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- TSI Investment Managers
- Sector
- PROK Health Care
- TSI Finance
- Exchange
- PROK Nasdaq
- TSI Nasdaq
- Market Cap
- PROK 206.0M
- TSI 237.5M
- IPO Year
- PROK N/A
- TSI N/A
- Fundamental
- Price
- PROK $1.50
- TSI $4.88
- Analyst Decision
- PROK Buy
- TSI
- Analyst Count
- PROK 5
- TSI 0
- Target Price
- PROK $4.50
- TSI N/A
- AVG Volume (30 Days)
- PROK 344.0K
- TSI 106.8K
- Earning Date
- PROK 03-21-2025
- TSI 01-01-0001
- Dividend Yield
- PROK N/A
- TSI 7.46%
- EPS Growth
- PROK N/A
- TSI N/A
- EPS
- PROK N/A
- TSI N/A
- Revenue
- PROK N/A
- TSI N/A
- Revenue This Year
- PROK N/A
- TSI N/A
- Revenue Next Year
- PROK N/A
- TSI N/A
- P/E Ratio
- PROK N/A
- TSI N/A
- Revenue Growth
- PROK N/A
- TSI N/A
- 52 Week Low
- PROK $1.34
- TSI $4.48
- 52 Week High
- PROK $4.44
- TSI $4.87
- Technical
- Relative Strength Index (RSI)
- PROK 41.47
- TSI 54.14
- Support Level
- PROK $1.50
- TSI $4.79
- Resistance Level
- PROK $1.67
- TSI $4.92
- Average True Range (ATR)
- PROK 0.10
- TSI 0.04
- MACD
- PROK -0.00
- TSI 0.01
- Stochastic Oscillator
- PROK 10.71
- TSI 63.64
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment, and others.